AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Buy” from Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $43.38.

A number of analysts recently weighed in on the stock. Oppenheimer upped their target price on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group upped their price target on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a report on Monday, December 9th. Needham & Company LLC upped their price target on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. UBS Group upped their price target on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $40.00 price target on shares of AtriCure in a report on Tuesday, December 17th.

Institutional Investors Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRC. Arcadia Investment Management Corp MI acquired a new position in AtriCure in the 3rd quarter valued at about $28,000. Heck Capital Advisors LLC acquired a new position in AtriCure during the 4th quarter worth approximately $60,000. Venturi Wealth Management LLC lifted its position in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares in the last quarter. KBC Group NV lifted its position in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after acquiring an additional 932 shares in the last quarter. Finally, R Squared Ltd acquired a new position in AtriCure during the 4th quarter worth approximately $89,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Down 1.8 %

Shares of NASDAQ:ATRC opened at $39.87 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The firm has a market capitalization of $1.94 billion, a PE ratio of -48.04 and a beta of 1.42. The firm’s 50-day moving average is $34.72 and its two-hundred day moving average is $30.25. AtriCure has a 1 year low of $18.94 and a 1 year high of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.